Sagimet Biosciences Inc Series A (SGMT) Stock Price, Quote & News

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 561 8600

Website: www.sagimet.com

Address:

155 Bovet Road, Suite 303, San Mateo, United States

John___wick44 Sep. 12 at 8:02 PM

$SGMT this could start getting real ugly. keep powder dry for under 5. next few months will be telling

1 · Reply

John___wick44 Sep. 12 at 1:06 PM

$SGMT they are going at this alone. dead money for 5 months. should be 15-20 right now. shorts know no news coming so piling on

2 · Reply

Whiskeyunderthebed Sep. 11 at 2:10 PM

$SGMT I'm expecting that they will have a partner by the end of the year for the Acne P3 study.

4 · Reply

Whiskeyunderthebed Sep. 10 at 6:02 PM

$SGMT

0 · Reply

biostock Sep. 10 at 2:36 PM

$SGMT Backlog of billions of Pimples for future treatment . $SPY $QQQ

0 · Reply

Amanda2024 Sep. 10 at 1:58 PM

$SGMT good price to load more

0 · Reply

rational1 Sep. 9 at 5:19 PM

$SGMT Last time this traded as many consecutive down days was late March into April. Hard bounce followed with just as many consecutive up days. Selling has been on low volume with no bad news nor downgrades. HCW conference taking place today and tomorrow. Snap back imminent. Nasdaq is fixed imo.

0 · Reply

John___wick44 Sep. 9 at 2:08 PM

$SGMT No news for 4-5 months so hard to see it not trade back to 5. it is a joke but how the market works

2 · Reply

yukselkaradeniz Sep. 8 at 6:23 PM

$SGMT

0 · Reply

Whiskeyunderthebed Sep. 8 at 3:04 PM

$SGMT added this morning at $7.04

1 · Reply

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Sep 7, 2025, 10:05 PM EDT - 7 days ago

Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 29, 2025, 11:19 AM EDT - 16 days ago

Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development

Aug 26, 2025, 7:00 AM EDT - 19 days ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Aug 13, 2025, 7:30 AM EDT - 4 weeks ago

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 7:00 AM EDT - 5 weeks ago

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jun 9, 2025, 7:00 AM EDT - 3 months ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Jun 4, 2025, 1:45 PM EDT - 3 months ago

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

Jun 4, 2025, 5:00 AM EDT - 3 months ago

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

May 22, 2025, 8:00 AM EDT - 4 months ago

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

May 8, 2025, 6:00 AM EDT - 4 months ago

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 12, 2025, 7:30 AM EDT - 6 months ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Mar 11, 2025, 8:00 AM EDT - 6 months ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Mar 7, 2025, 4:27 PM EST - 6 months ago

Sagimet Biosciences' Denifanstat Should Be Worth More Today

Nov 14, 2024, 3:56 PM EST - 10 months ago

Sagimet: More Than Just A MASH Drug Development Biotech

Nov 12, 2024, 6:30 AM EST - 10 months ago

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Oct 18, 2024, 3:10 PM EDT - 11 months ago

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Oct 11, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Oct 1, 2024, 12:05 AM EDT - 1 year ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 12, 2024, 7:30 AM EDT - 1 year ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Jul 31, 2024, 12:24 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Jun 6, 2024, 5:00 AM EDT - 1 year ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

May 16, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

May 15, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 7, 2024, 8:00 AM EDT - 1 year ago

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Apr 26, 2024, 12:23 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Mar 25, 2024, 6:15 AM EDT - 1 year ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Jan 25, 2024, 8:58 PM EST - 1 year ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Jan 24, 2024, 1:55 PM EST - 1 year ago

Sagimet: Additional Upside Possible After Latest NASH Data Release

Jan 23, 2024, 5:45 PM EST - 1 year ago

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Jan 22, 2024, 11:10 PM EST - 1 year ago

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Jan 22, 2024, 7:00 AM EST - 1 year ago

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Dec 4, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Nov 28, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

Nov 22, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 13, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 10, 2023, 8:30 AM EST - 2 years ago

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Oct 24, 2023, 11:00 AM EDT - 2 years ago

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023

Oct 18, 2023, 4:05 PM EDT - 2 years ago

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

Sep 27, 2023, 4:05 PM EDT - 2 years ago

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Sep 27, 2023, 2:48 PM EDT - 2 years ago

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

Aug 21, 2023, 4:02 PM EDT - 2 years ago

Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Aug 15, 2023, 4:04 PM EDT - 2 years ago

Sagimet Biosciences Announces Closing of Underwriters' Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering

John___wick44 Sep. 12 at 8:02 PM

$SGMT this could start getting real ugly. keep powder dry for under 5. next few months will be telling

1 · Reply

John___wick44 Sep. 12 at 1:06 PM

$SGMT they are going at this alone. dead money for 5 months. should be 15-20 right now. shorts know no news coming so piling on

2 · Reply

Whiskeyunderthebed Sep. 11 at 2:10 PM

$SGMT I'm expecting that they will have a partner by the end of the year for the Acne P3 study.

4 · Reply

Whiskeyunderthebed Sep. 10 at 6:02 PM

$SGMT

0 · Reply

biostock Sep. 10 at 2:36 PM

$SGMT Backlog of billions of Pimples for future treatment . $SPY $QQQ

0 · Reply

Amanda2024 Sep. 10 at 1:58 PM

$SGMT good price to load more

0 · Reply

rational1 Sep. 9 at 5:19 PM

0 · Reply

John___wick44 Sep. 9 at 2:08 PM

$SGMT No news for 4-5 months so hard to see it not trade back to 5. it is a joke but how the market works

2 · Reply

yukselkaradeniz Sep. 8 at 6:23 PM

$SGMT

0 · Reply

Whiskeyunderthebed Sep. 8 at 3:04 PM

$SGMT added this morning at $7.04

1 · Reply

rational1 Sep. 5 at 10:16 PM

$SGMT

0 · Reply

biostock Sep. 5 at 4:26 PM

$SGMT Billions in TAM. $24 coming $SPY $QQQ

0 · Reply

NVDAMillionaire Sep. 5 at 3:27 PM

$SGMT Outstanding article that hits the mark on SGMT's current state. So if you want to refresh your SGMT insights or learn about SGMT from scratch, this is a must read. https://beyondspx.com/quote/SGMT/sagimet-biosciences-unlocking-metabolic-pathways-with-fasn-inhibition-nasdaq-sgmt#analysis

1 · Reply

shibadad Sep. 5 at 2:17 PM

$SGMT Happel also noted TVB 3567 is a next gen molecule and is more potent than deni. It will require less dosing in acne. However, my research found that Ascletis owns the Chinese development rights to TVB 3567 but there are no trials of any kind for that molecule in China. Not sure what to make of that.

2 · Reply

John___wick44 Sep. 5 at 1:58 PM

$SGMT combo therapy is the future. they are not going to run a p3

0 · Reply

John___wick44 Sep. 5 at 3:10 AM

$SGMT they also stated hair thinning could have been related to covid not the drug as it had not shown that before. 3-5 billion people within 2 years

0 · Reply

shibadad Sep. 4 at 5:20 PM

$SGMT Also, at the Cantor Conference, Happel said that the cash runway extends to the beginning of 2028 and covers P2b MASH combo trials as well as the TVB 3567 acne trials. So there's minimal (but not zero) risk that they raise cash now at these levels.

0 · Reply

shibadad Sep. 4 at 5:15 PM

$SGMT At the Cantor Conference, Happel said the proposed guidance on liver biopsies was a "gift" and that he would have been unhappy if they had started P3 trials with biopsies required only to have requirements change. They plan to discuss with the FDA soon regarding the proposed changes. He also mentioned the IP coverage for TVB 3567 extending out as far as 2046 in acne and the IP for FASN combos out to 2044. They seem very bullish on their acne prospects and noted that their intention is to GIA in acne and take TVB 3567 all the way to commercialization which he said would not be difficult. They are also going to explore FASN inhibitors in other derm conditions but did not specify.

0 · Reply

Amanda2024 Sep. 4 at 3:25 PM

$SGMT oops

0 · Reply

John___wick44 Sep. 4 at 3:36 AM

$SGMT no momey raise coming until 2027 of it is not sold by then. This is a 2-4 billion dollar company easily

0 · Reply

AnyaGirl Sep. 2 at 10:30 AM

$SGMT poop

1 · Reply

BearTamerTrading Aug. 30 at 6:49 PM

$BTAI $IINN $KNW $SGMT $USBC They hate on me in public because I have proven my ability to thousands but want to follow me to get my plays. Make it make sense 😂. Now you’re blocked.

1 · Reply

Market Cap	219.85M
Revenue (ttm)	0.00
Net Income (ttm)	-45.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	377,300
Avg Vol	667,636
Day's Range	N/A - N/A
Shares Out	32.52M
Stochastic %K	1%
Beta	3.34
Analysts	Strong Sell
Price Target	$23.22